Floatz logo

Ganciclovir

Encephalopathy

Small moleculePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

23 Active assets in the Encephalopathy cohort.

Asset / SponsorPhaseRating
Galantamine Hydrobromide
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3B
Fremanezumab
Hospital Clínico Universitario de Valladolid
Phase 4B
Donanemab
Eli Lilly and Company
Phase 3B
Live Combined Bifidobacterium
Beijing Friendship Hospital
Phase 4B
Live Combined Bifidobacterium,Lactobacillus And Enterococcus Capsules
Beijing Friendship Hospital
Phase 4B

View all 43 →

Same molecule, other indications

Ganciclovir is also rated in:

cytomegalovirus retinitisDormant
A
Indicative ·
82 / 100
View asset →
HIV infectious diseaseDormant
BBB
Indicative ·
76 / 100
View asset →
cytomegalovirus infectionDormant
BB
Indicative ·
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →